Filing summary
Entity mismatch: The supplied filing is for Anzu Special Acquisition Corp I, a SPAC—not Envoy Medical, Inc. This summary reflects the filing text provided and should not be attributed to Envoy Medical.
Business context and reporting period
The unaudited Form 10-Q covers the three months ended March 31, 2022. Anzu was a blank-check company seeking a business combination, with a stated focus on industrial businesses using transformative technologies. It had not begun operating or generated operating revenue.
Financial results and liquidity
- Revenue: No operating revenue. Trust-account interest was $40,410.
- Net income: $12.46 million, compared with a $1.47 million net loss in Q1 2021. The 2022 result was primarily driven by a $14.40 million noncash gain from the decrease in warrant-liability fair value; formation and operating costs were $1.49 million.
- Cash flow: Operating cash use was $772,740. Financing provided $750,000 from a related-party working-capital loan, producing a $22,740 decrease in cash.
- Cash and liquidity: Cash outside the trust was $127,105 at March 31, 2022, versus $149,845 at year-end 2021. Working-capital deficit was $3.30 million, compared with $1.82 million at year-end.
- Trust and redemption shares: Trust investments were $425.08 million. All 42.5 million public Class A shares were classified as temporary equity at a $10.00-per-share redemption value.
- Debt and obligations: The related-party working-capital loan was $750,000 at quarter-end; the company drew another $750,000 on April 1, bringing the amount outstanding to $1.5 million by the report date. A $14.875 million deferred underwriting fee is payable only if a business combination closes.
- Margins: Not meaningful because the company had no operating revenue.
Material changes versus the prior comparable period
- Net income improved from a $1.47 million loss in Q1 2021 to $12.46 million in Q1 2022, mainly because warrant-liability remeasurement produced a gain in 2022 rather than an expense in 2021.
- Operating costs increased to $1.49 million from $966,277. Cash outside the trust fell from $2.15 million at March 31, 2021 to $127,105 at March 31, 2022.
- Warrant liabilities fell to $6.67 million from $21.06 million at December 31, 2021. The forward-purchase agreement asset was $515,540, down from $1.00 million at year-end.
Outlook, risks, contingencies, and unusual items
- The company had until March 4, 2023, unless extended, to complete a business combination; otherwise it was required to redeem public shares and liquidate. Warrants could expire worthless if no combination closed.
- Management said additional funding might be needed and the sponsor was not obligated to provide funds beyond the stated loan facility. The filing states that these conditions raise substantial doubt about the company’s ability to continue as a going concern if a business combination is not completed.
- Forward-purchase agreements contemplated up to $80 million of convertible notes and up to $40 million of forward-purchase securities at a business-combination closing, subject to conditions and further terms. The filing reports no issuance of those securities as of quarter-end.
- Management cited potential impacts from COVID-19 and the Russia-Ukraine conflict, which it said could not then be determined. Proposed SEC SPAC rules could increase transaction costs and affect the ability or timing of completing a combination.
- Disclosure controls were deemed ineffective because of a material weakness in accounting for complex financial instruments and temporary equity, following prior financial-statement restatements. Management said remediation efforts were ongoing and offered no assurance they would be effective.
- There were no material legal proceedings reported outside the ordinary course of business.
Important facts for investors to verify
- Confirm the intended issuer: this filing identifies Anzu Special Acquisition Corp I, not Envoy Medical, Inc.
- Assess cash runway, the working-capital loan terms and availability, and the company’s ability to fund its search and transaction costs.
- Verify business-combination status, any extension of the March 4, 2023 deadline, and the conditions and final terms of the forward-purchase agreements.
- Review the warrant-liability and forward-purchase fair-value assumptions, since remeasurement materially affected reported earnings.
- Track remediation of the material weakness and whether disclosure controls become effective.
- Check the filing’s inconsistent monthly administrative-fee figures: $40,521 in the notes versus $40,251 in MD&A.